Détail de l'auteur
Auteur Wagner KR |
Documents disponibles écrits par cet auteur



![]()
Meeting report: the 2020 FSHD International Research Congress
Kyba M, Bloch RJ, Dumonceaux J, et al.
Skeletal Muscle, 2020, 10, 1, p 36
Revue : Skeletal Muscle, 10, 1 Titre : Meeting report: the 2020 FSHD International Research Congress Type de document : Article Auteurs : Kyba M ; Bloch RJ ; Dumonceaux J ; Harper SQ ; van der Maarel SM ; Sverdrup FM ; Wagner KR ; van Engelen B ; Chen YW Année de publication : 08/12/2020 Pages : p 36 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 33292505 / DOI : 10.1186/s13395-020-00253-2
N° Profil MNM : 2020122 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/33292505 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy
Wagner KR, Abdel-Hamid HZ, Mah JK, et al.
Neuromuscular disorders : NMD, 2020, 30, 6, p 492
Revue : Neuromuscular disorders : NMD, 30, 6 Titre : Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy Type de document : Article Auteurs : Wagner KR ; Abdel-Hamid HZ ; Mah JK ; Campbell C ; Guglieri M ; Muntoni F ; Takeshima Y ; McDonald CM ; Kostera-Pruszczyk A ; Karachunski P ; Butterfield RJ ; Mercuri E ; Fiorillo C ; Bertini ES ; Tian C ; Statland J ; Sadosky AB ; Purohit VS ; Sherlock SP ; Palmer JP ; Binks M ; Charnas L ; Marraffino S ; Wong BL Editeur : England Année de publication : 06/2020 Pages : p 492 Langues : Anglais (eng) Lien associé : NCT02907619 Pubmed / DOI : Pubmed : 32522498 / DOI : 10.1016/j.nmd.2020.05.002
N° Profil MNM : 2020061 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32522498 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Longitudinal functional and imaging outcome measures in FKRP limb-girdle muscular dystrophy
Leung DG, Bocchieri AE, Ahlawat S, et al.
BMC neurology, 2020, 20, 1, p 196
Revue : BMC neurology, 20, 1 Titre : Longitudinal functional and imaging outcome measures in FKRP limb-girdle muscular dystrophy Type de document : Article Auteurs : Leung DG ; Bocchieri AE ; Ahlawat S ; Jacobs MA ; Parekh VS ; Braverman V ; Summerton K ; Mansour J ; Bibat G ; Morris C ; Marraffino S ; Wagner KR Année de publication : 05/2020 Pages : p 196 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32429923 / DOI : 10.1186/s12883-020-01774-5
N° Profil MNM : 2020052 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32429923 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic
Veerapandiyan A, Wagner KR, Apkon S, et al.
Muscle & Nerve, 2020
Revue : Muscle & Nerve Titre : The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic Type de document : Article Auteurs : Veerapandiyan A, Auteur ; Wagner KR ; Apkon S ; McDonald CM ; Mathews KD ; Parsons JA ; Wong BL ; Eichinger K ; Shieh PB ; Butterfield RJ ; Rao VK ; Smith EC ; Proud CM ; Connolly AM ; Ciafaloni E Editeur : United States Année de publication : 04/2020 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32329920 / DOI : 10.1002/mus.26902
N° Profil MNM : 2020042 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32329920 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy
Lek A, Zhang Y, Woodman KG, et al.
Science translational medicine, 2020, 12, 536
Revue : Science translational medicine, 12, 536 Titre : Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy Type de document : Article Auteurs : Lek A, Auteur ; Zhang Y ; Woodman KG ; Huang S ; DeSimone AM ; Cohen J ; Ho V ; Conner J ; Mead L ; Kodani A ; Pakula A ; Sanjana N ; King OD ; Jones PL ; Wagner KR ; Lek M ; Kunkel LM Editeur : United States Année de publication : 03/2020 Langues : Anglais (eng) Pubmed / DOI : Pubmed : 32213627 / DOI : 10.1126/scitranslmed.aay0271
N° Profil MNM : 2020032 En ligne : http://www.ncbi.nlm.nih.gov/pubmed/32213627 Avis des lecteurs Aucun avis, ajoutez le vôtre !
(mauvais) 15 (excellent)
![]()
Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT)
Willmann R, Lee J, Turner C, et al.
Disease models & mechanisms, 2020, 13, 2
Permalink![]()
A decade of optimizing drug development for rare neuromuscular disorders through TACT
Wagner KR, de Luca A, Caizergues D, et al.
Nature reviews. Drug discovery, 2020, 19, 1, p 1
Permalink![]()
Facioscapulohumeral Muscular Dystrophies
Wagner KR
Continuum (Minneapolis, Minn.), 2019, 25, 6, p 1662
Permalink![]()
Diabetes, Metformin, and Cancer Risk in Myotonic Dystrophy Type I
Alsaggaf R, Pfeiffer RM, Wang Y, et al.
International journal of cancer, 2019
Permalink![]()
Stem cell-based therapies for Duchenne muscular dystrophy.
Sun C, Serra C, Lee G, et al.
Experimental neurology, 2019, 323
Permalink![]()
AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice.
Nance ME, Shi R, Hakim CH, et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 2019, 27, 9, p. 1568-1585
Permalink![]()
Benign tumors in myotonic dystrophy type I target disease-related cancer sites
Alsaggaf R, St George DMM, Zhan M, et al.
Annals of clinical and translational neurology, 2019, 6, 8, p 1510
Permalink![]()
The NIH Toolbox for cognitive surveillance in Duchenne muscular dystrophy
Thangarajh M, Kaat AJ, Bibat G, et al.
Annals of clinical and translational neurology, 2019, 6, 9, p 1696
Permalink![]()
Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity
Alsaggaf R, Alsaggaf R, St George DMM, et al.
JNCI cancer spectrum, 2018, 2, 4
Permalink![]()
Cardiac Management of the Patient With Duchenne Muscular Dystrophy
Buddhe S, Buddhe S, Cripe L, et al.
Pediatrics, 2018, 142, S2, p S72
Permalink![]()
Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy
Leigh F, Leigh F, Ferlini A, et al.
Pediatrics, 2018, 142, S2, p S5
Permalink![]()
A Transition Toolkit for Duchenne Muscular Dystrophy
Trout CJ, Trout CJ, Case LE, et al.
Pediatrics, 2018, 142, S2, p S110
Permalink![]()
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
Birnkrant DJ, Bushby K, Bann CM, et al.
The Lancet. Neurology, 2018, 17, 3, p 251
Permalink![]()
Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
Chen JC, King OD, Zhang Y, et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 2016, 24, 8, p 1405
Permalink![]()
Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia 21 September 2015
Tawil R, Mah JK, Baker S, et al.
Neuromuscular disorders : NMD, 2016, 26, 7, p 462
Permalink![]()
Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures
Kornegay JN, Bogan DJ, Bogan JR, et al.
Skeletal Muscle, 2016, 6, 14, p. 1-17
Permalink![]()
Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy
Jones TI, King OD, Himeda CL, et al.
Clinical Epigenetics, 2015, 7
Permalink![]()
Results of a Two-Year Pilot Study of Clinical Outcome Measures in Collagen VI- And Laminin alpha2-related Congenital Muscular Dystrophies
Meilleur KG, Jain MS, Hynan LS, et al.
Neuromuscular disorders : NMD, 2015, 25, 1, p 43
Permalink![]()
The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development
Heslop E, Csimma C, Straub V, et al.
Orphanet journal of rare diseases, 2015, 10
Permalink![]()
Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy
Leung DG, Herzka DA, Thompson WR, et al.
Annals of neurology, 2014, 76, 4, p 541
Permalink